Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Profiling of Exceptional Responders to Cancer Therapy.

The oncologist - 1 Mar 2021

Bilusic Marijo, Girardi Daniel, Zhou Yan, Jung Kyungsuk, Pei Jianming, Slifker Michael, Chen Qingrong, Meerzaman Daoud, Alpaugh Katherine, Young Denise, Flieder Douglas, Gray Phillip, Plimack Elizabeth

Abstract excerpt

BACKGROUND: The vast majority of metastatic cancers cannot be cured. Palliative treatment may relieve disease symptoms by stopping or slowing cancer growth and may prolong patients' lives, but almost all patients will inevitably develop disease progression after initial response. However, for reasons that are not fully understood, a very few patients will have extraordinary durable responses to standard...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferroptosis and cancer prognosis

Share to Medical Oncology

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 33210795
DOI: 10.1002/onco.13600
PMCID: PMC7930427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Profiling of Exceptional Responders to Cancer Therapy.PMID 33210795Read ↗

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.Semantic proximity Read ↗

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.Semantic proximity Read ↗

Rare Germline Variants in Immune and Drug Target Genes Among Cancer Exceptional RespondersSemantic proximity Read ↗

What have we learned from exceptional tumour responses?: Review and perspectives.Semantic proximity Read ↗

Genomic landscape of extraordinary responses in metastatic breast cancer.Semantic proximity Read ↗

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.Semantic proximity Read ↗

Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancerSemantic proximity Read ↗

Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaSemantic proximity Read ↗

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic CancerSemantic proximity Read ↗

Transforming Biomarker Development with Exceptional Responders.Semantic proximity Read ↗

RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?Semantic proximity Read ↗

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.